Skip to main content

Table 2 Clinical trial populations included in analyses

From: Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

Analysis

Clinical Trials

EVOLVE-1

Phase 3 DB

EVOLVE-2

Phase 3 DB

REGAIN

Phase 3

DB and OL

ART-01

Phase 2 DB

CGAB

Phase 2 DB

CGAJ

Phase 3 OL

Pharmacokinetica

X

X

X

 

X

X

Baseline comparison

X

X

X

   

Efficacy outcomes

X

X

Xb

   

Safety outcomes

 Phase 3_Pooled

X

X

Xb

   

 All GMB Exposure

X

X

X

X

X

X

  1. Abbreviations: All GMB Exposure Patients treated with any GMB dose in any duration, DB Double blind, GMB Galcanezumab, OL Open label, Phase 3_Pooled, all patients from the 3 placebo-controlled phase 3 trials
  2. aIncludes results from phase 2 and 3 studies with 28-day or monthly dosing regimens
  3. bIncludes results from DB phase of trials only
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us